First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug

After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.